Business School, Jilin University, Changchun 130012, China.
International Business School Suzhou, Xi'an Jiaotong-Liverpool University, Suzhou 215123, China.
Int J Environ Res Public Health. 2020 Jan 14;17(2):516. doi: 10.3390/ijerph17020516.
Medical innovation has consistently been an essential subject and a source of support for public health research. Furthermore, improving the level of medical research and development is of great concern in this field. This paper highlights the role of big data in public medical innovation. Based on a sample of China's listed firms in the medical industry from 2013 to 2018, this paper explores the exogenous shock effect of China's big data medical policy. Results show that the construction of the medical big data platform effectively promotes innovation investment and the innovation patent of medical firms. In addition, the heterogeneity of this promoting effect is reflected in firm size through the overcoming of different innovation bottlenecks. The research conclusions support the positive significance of the macro-led implementation of the medical big data platform, and suggest that the positive economic externalities generated by this policy are critical to public health.
医学创新一直是公共卫生研究的重要课题和支持来源。此外，提高医学研究和开发水平是该领域关注的重点。本文强调了大数据在公共医疗创新中的作用。本文基于 2013 年至 2018 年中国医疗行业上市公司的样本，探讨了中国大数据医疗政策的外生冲击效应。结果表明，医疗大数据平台的建设有效促进了医疗企业的创新投资和创新专利。此外，通过克服不同的创新瓶颈，这种促进效应在企业规模上表现出异质性。研究结论支持了宏观层面实施医疗大数据平台的积极意义，并表明该政策产生的积极经济外部性对公共卫生至关重要。
